Ivax/Serono Oral MS Therapy Mylinax Efficacy Trials Planned For 2004
This article was originally published in The Pink Sheet Daily
Executive Summary
Exact nature of the trials will be determined following discussion with FDA, Ivax says. Trial design could be a challenge in light of the troubled regulatory history of injectable cladribine for MS, previously pursued by J&J.
You may also be interested in...
Rebif Gains New Multiple Sclerosis Rx Share Following Tysabri Withdrawal
Rebif is the leader in new prescription growth with a 22.4% share, an all-time high, at the end of March, Serono says. The company is focusing marketing of Rebif on efficacy, a message to which Tysabri helped draw attention. Serono expects Rebif to emerge as the global MS leader by 2006.
Pfizer Looks To Enter Oral Anti-Thrombotic Market Through Schering AG Deal
Company in-licenses Schering AG’s preclinical oral ADP receptor antagonist line; agents are targeted for chronic use in prophylaxis of arterial thrombosis and other CV events. Pfizer has one marketed anti-thrombotic, none in clinical development.